Preventive Endocrinology In Maryland

Three new therapies are reshaping how physicians approach obesity, diabetes, cholesterol, heart disease, and kidney protection. GLP-1 multi agonists, PCSK9 targeted therapies, and SGLT2 inhibitors now influence multiple biologic systems simultaneously. This broader perspective reflects how interconnected the body truly is. This article discusses how these therapies may improve long term metabolic and cardiovascular health through a more integrated and personalized strategy.